scholarly journals Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study

2008 ◽  
Vol 193 (6) ◽  
pp. 485-492 ◽  
Author(s):  
S. Charles Schulz ◽  
Mary C. Zanarini ◽  
Anthony Bateman ◽  
Martin Bohus ◽  
Holland C. Detke ◽  
...  
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Rating Scale ◽  
Borderline Personality ◽  
Controlled Study ◽  
Double Blind ◽  
Point Change ◽  
End Point ◽  
Primary Efficacy Measure ◽  
Efficacy Measure

BackgroundDespite the prevalence and clinical significance of borderline personality disorder, its treatment remains understudied.AimsTo evaluate treatment with variably dosed olanzapine in individuals with borderline personality disorder.MethodIn this 12-week randomised, double-blind trial, individuals received olanzapine (2.5–20 mg/day; n=155) or placebo (n=159) (trial registry: NCT00091650). The primary efficacy measure was baseline to end-point change on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN–BPD) using last-observation-carried-forward methodology.ResultsBoth olanzapine and placebo groups showed significant improvements but did not differ in magnitude at end-point (76.56 v. 76.25, P=0.661). Response rates (50% reduction in ZAN–BPD) were 64.7% with olanzapine and 53.5% with placebo (P=0.062); however, time to response was significantly shorter for olanzapine (P=0.022). Weight gain was significantly greater (2.86 v. 70.35 kg, P50.001), with higher incidence of treatment-emergent abnormal high levels of prolactin for the olanzapine group.ConclusionsIndividuals treated with olanzapine and placebo showed significant but not statistically different improvements on overall symptoms of borderline personality disorder. The types of adverse events observed with olanzapine treatment appeared similar to those observed previously in adult populations.

scholarly journals A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder

2021 ◽  
pp. 1-6
Author(s):  
Jon E. Grant ◽  
Stephanie Valle ◽  
Eve Chesivoir ◽  
Dustin Ehsan ◽  
Samuel R. Chamberlain
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Repeated Measures ◽  
Rating Scale ◽  
Safety Data ◽  
Borderline Personality ◽  
Small Sample ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Background Borderline personality disorder is associated with impaired quality of life and has a number of untoward public health associations. There is no established first-line pharmacological treatment for borderline personality disorder, and available options are not suitable for all individuals. Aims To evaluate brexpiprazole, which has effects on the dopaminergic and serotonergic systems, for the reduction of borderline personality disorder symptoms. Method Eighty adults with borderline personality disorder were recruited for a randomised, double-blind placebo-controlled study. Participants received 12-week treatment with brexpiprazole (1 mg/day for 1 week, then increasing to 2 mg/day) or placebo in a parallel design. The primary efficacy outcome measure was the clinician-rated Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD). Safety data were collected. Effects of active versus placebo treatment were characterised with linear repeated measures models. Results There was a significant interaction between treatment and time on the ZAN-BPD scale (P = 0.0031), solely because of differentiation specifically at week 12. Brexpiprazole was generally well tolerated. Secondary measures did not result in statistically significant differences from placebo. Conclusions Brexpiprazole appears to have some possible effect on borderline personality disorder symptoms, but further studies are needed because of the significant effects evident, specifically at the final time point. These findings also need to be viewed cautiously, given the small sample size, large drop-out rate and robust placebo response.

scholarly journals Exploring nonverbal synchrony in borderline personality disorder: A double‐blind placebo‐controlled study using oxytocin

2019 ◽  
Vol 59 (2) ◽  
pp. 186-207 ◽  
Author(s):  
Fabian Ramseyer ◽  
Andreas Ebert ◽  
Patrik Roser ◽  
Marc‐Andreas Edel ◽  
Wolfgang Tschacher ◽  
...  
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Borderline Personality ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nonverbal Synchrony

Aripiprazole in the Treatment of Patients With Borderline Personality Disorder: A Double-Blind, Placebo-Controlled Study

2006 ◽  
Vol 163 (5) ◽  
pp. 833-838 ◽  
Author(s):  
Marius K. Nickel ◽  
Moritz Muehlbacher ◽  
Cerstin Nickel ◽  
Christian Kettler ◽  
Francisco Pedrosa Gil ◽  
...  
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Borderline Personality ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Acetaminophen Reduces Distrust in Individuals With Borderline Personality Disorder Features

2017 ◽  
Vol 6 (1) ◽  
pp. 145-154 ◽  
Author(s):  
Ian D. Roberts ◽  
Ian Krajbich ◽  
Jennifer S. Cheavens ◽  
John V. Campo ◽  
Baldwin M. Way
Keyword(s):  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Personality Assessment ◽  
Personality Assessment Inventory ◽  
Borderline Personality ◽  
Trust Game ◽  
Placebo Condition ◽  
Double Blind ◽  
Adult Participants ◽  
Interpersonal Difficulties

People with borderline personality disorder (BPD) tend to distrust others. We hypothesized that acetaminophen might reduce distrust in people with high BPD features because disordered affective responses are partially responsible for the interpersonal difficulties of people with BPD features, and acetaminophen has been shown in multiple studies to reduce negative affect. Using a double-blind, parallel-arm design, 284 young adult participants were administered either acetaminophen (1,000 mg; acute) or placebo and subsequently completed an economic trust game. BPD features were assessed with the Personality Assessment Inventory–Borderline Features scale. Participants with elevated BPD features showed less trust in their partners in the placebo condition but increased trust in the acetaminophen condition. Acetaminophen did not change expectations of trustee’s trustworthiness and did not impact trusting behavior in participants low in BPD features. Our results indicate that acetaminophen may reduce the behavioral distrust exhibited at high levels of BPD features.

Sign in / Sign up

Export Citation Format

Share Document